Commercial Launch of Innovative Multi-Cancer Early Detection

Caris Life Sciences (CAI) has officially launched 'Caris Detect,' a multi-cancer early detection (MCED) blood test that combines AI modeling with next-generation sequencing (NGS) technology, in the U.S. market. This test goes beyond simple genetic mutation snapshot analysis, integrating whole-genome sequencing (WGS) and whole-transcriptome sequencing (WTS) to detect subtle signals of cancer through an innovative liquid biopsy approach. It is designed to overcome the limitations of existing diagnostic methods and provide patients with a non-invasive and highly precise opportunity for early cancer detection.

Data Obtained Through ACHIEVE 1 Clinical Validation Study

The commercial launch of Caris Detect is based on robust efficacy data from the ACHIEVE 1 study, a large-scale clinical validation study involving 3,014 subjects. Clinical results show that, despite the increasing difficulty of detection as cancer stage decreases, the test achieved a sensitivity of 56.8% in Stage I and 67.7% in Stage II, demonstrating a high level of cancer signal detection capability with a combined sensitivity of 60.3% for Stages I and II. Sensitivity increased as the stage progressed, reaching 79.0% in Stage III and 98.6% in Stage IV. Notably, it showed a high sensitivity of 81.3% in head and neck cancer, which is often difficult to treat, while breast cancer showed a relatively lower value of 53.0%.

Synergy Between AI Modeling and Proprietary Genomic Database

Although Caris is a latecomer in the diagnostics market, it claims a strong competitive advantage due to its unique AI platform, which has learned from over 1 million profiled data sets and 50 billion molecular markers. This high-performance algorithm comprehensively analyzes various biological signals, including circulating tumor DNA (ctDNA), RNA, fragmentomics, and nucleosome positioning, in the blood to identify subtle signs of early cancer. This AI-based analysis is considered a new milestone in precision medicine, significantly reducing false-negative rates even with small sample sizes.

Regulatory Status and Positioning in a Highly Competitive Market

Caris Detect was launched as a laboratory-developed test (LDT) through a CLIA-certified laboratory, rather than through the FDA approval pathway. This can be interpreted as a strategic decision to quickly commercialize the product, secure early revenue, and gain market share. In the global MCED market, which is estimated at $1.3 billion to $1.46 billion in 2025 and is projected to grow to as much as $6.49 billion by the mid-2030s, Caris will inevitably face fierce competition for market share with strong leaders such as Grail's 'Galleri' and Guardant Health's 'Shield'.

Building a Comprehensive Diagnostic Portfolio and Synergistic Effects

With the launch of Caris Detect, Caris has completed its comprehensive cancer care diagnostic portfolio, which includes existing genomic profiling tests for treatment selection, 'Cancer Seek' and 'Caris Assure'. This creates an ecosystem that encompasses the entire patient journey, from preventive screening to treatment target matching, thereby increasing the value of the platform. Furthermore, Caris, which debuted on the Nasdaq in June 2025, raised $494.1 million and was valued at approximately $5.3 billion, and is expected to be a key driver of the company's mid- to long-term revenue growth.